Although it is conceivable that EZH2 inhibitors may reverse lineage transformation, based on pre-clinical experimental models, in the clinic it may be most beneficial to use them upfront in combination with EGFR-TKIs to prevent SCLC transformation, particularly in EGFR/TP53/RB1 triple mutant lung cancers. Here, TP53 is linked to small cell lung carcinoma.